MCKESSON CORPORATION

McKesson Corporation has finalized its acquisition of Core Ventures, which includes Florida Cancer Specialists & Research Institute, to expand community-based oncology care services.

Trinity Life Sciences has formed a strategic collaboration with Ontada, a McKesson business, to provide life sciences companies with real-time oncology insights for pre- and post-launch decision making.

• Stanford Health Care has expanded its partnership with Atropos Health to embed real-world evidence directly into clinical workflows and encounter notes, enhancing point-of-care decision making without disrupting physician workflow. • The integration will work alongside Stanford's ambient AI provider, DAX from Microsoft, to generate evidence that helps clinicians finalize their notes while remaining within their existing EHR environment. • This advancement builds on Stanford's multi-year collaboration with Atropos Health, which began as the "Green Button" research project at Stanford Medicine in 2011 and has evolved to support over 2,000 affiliated physicians.

• Harrow has executed a five-year strategic supply and development agreement with the current contract manufacturing organization for TRIESENCE®, ensuring stable supply of the ocular corticosteroid. • The company has begun developing an enhanced version of TRIESENCE®, with plans to submit a new drug application (NDA) to the FDA by the end of 2027. • TRIESENCE® is FDA-approved for visualization during vitrectomy and treatment of ocular inflammatory conditions unresponsive to topical corticosteroids, addressing a product previously on the FDA's Drug Shortage List.

• Remote clinical pharmacists reviewed over 5,700 oncology orders in community practices, identifying intervention opportunities in 60% of cases, demonstrating significant clinical impact. • Integration of pharmacists led to $5.9 million reduction in medication costs and $1.4 million practice margin improvement, achieving 415% return on investment over 12 months. • Pharmacist interventions focused on patient-centered care (36%), dose optimization (35%), and therapeutic interchange (30%), while saving over 800 hours of provider time.

• A redesigned clinical decision support tool has dramatically improved biomarker documentation rates, increasing from 69% to 78% in NSCLC and 34% to 61% in mCRPC cases. • The enhanced tool aligns with typical biomarker testing timelines and reduces physician "click fatigue" by streamlining the documentation process in cancer care workflows. • Researchers plan to expand this optimized approach across 30+ cancer types, aiming to improve treatment decision support while maintaining clinical efficiency.

• Despite exceptional clinical outcomes, cell and gene therapies face significant access challenges with many patients having to travel over 50 miles to treatment centers, according to McKesson's 2024 report. • A staggering 99% of surveyed oncologists view cell and gene therapies as groundbreaking innovations, with 94% reporting significant patient quality-of-life improvements. • Current healthcare payment systems struggle to accommodate the high upfront costs of these therapies, prompting calls for innovative payment models including value-based and annuity-type arrangements.

Dr. Lalan Wilfong, a veteran oncologist from Texas Oncology, joins Thyme Care as Senior Vice President of Value-Based Care to revolutionize oncology practice transformation.

• The 2023 cisplatin shortage led to a 15% decrease in its usage at U.S. oncology centers, with significant increases in alternative treatments including carboplatin (40%), paclitaxel (24%), and cetuximab (15%). • Drug administration patterns shifted significantly during the shortage period, with most changes occurring in curative-intent treatments and resulting in less guideline-concordant care according to NCCN recommendations. • The shortage triggered persistent cost increases for both payers and patients, with particularly high financial impact when switching to cetuximab, which lacks generic alternatives.

McKesson Corporation has established InspiroGene, a specialized business unit dedicated to streamlining the commercialization of cell and gene therapies through comprehensive support services.